LumiraDx (LumiraDx) Gross-Profit-to-Asset % : -10.79% (As of Jun. 2023)

View and export this data going back to 2021. Start your Free Trial

What is LumiraDx Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. LumiraDx's annualized Gross Profit for the quarter that ended in Jun. 2023 was $-39.60 Mil. LumiraDx's average Total Assets over the quarter that ended in Jun. 2023 was $366.96 Mil. Therefore, LumiraDx's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 was -10.79%.

LumiraDx Gross-Profit-to-Asset % Historical Data

The historical data trend for LumiraDx's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LumiraDx Gross-Profit-to-Asset % Chart

LumiraDx Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Gross-Profit-to-Asset %

10.28

26.13

-6.50

LumiraDx Quarterly Data
	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial								3.14	6.04	-78.28	-1.69	-10.79

Competitive Comparison of LumiraDx's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, LumiraDx's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LumiraDx's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, LumiraDx's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where LumiraDx's Gross-Profit-to-Asset % falls into.

LumiraDx Gross-Profit-to-Asset % Calculation

LumiraDx's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	-35.302	/	( (644.78	+	441.013)	/ 2 )
	=	-35.302	/	542.8965
	=	-6.50 %

LumiraDx's annualized Gross-Profit-to-Asset % for the quarter that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Jun. 2023 )	/	( (Total Assets (Q: Mar. 2023 )	+	Total Assets (Q: Jun. 2023 ))	/ count )
	=	-39.604	/	( (392.308	+	341.607)	/ 2 )
	=	-39.604	/	366.9575
	=	-10.79 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Jun. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

LumiraDx Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of LumiraDx's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

LumiraDx (LumiraDx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » LumiraDx Ltd (OTCPK:LMDWF) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

LMDXF:USA

Address

C/o Ocorian Trust (Cayman) Ltd, Windward 3, P.O. Box 1350, Regatta Office Park, Grand Cayman, CYM, KY1-1108

Website

https://www.lumiradx.com

LumiraDx Ltd is a next-generation point of care diagnostics company. It manufactures and commercializes an innovative diagnostic Platform that supports a broad menu of tests with lab comparable performance at the point of care. Geographical presence in United States, Italy, UK, Germany, Colombia, Sweden and Other countries. Majority revenue derives from U.S.